A new study highlights age, allergies, smoking, and history of angioedema as non-genetic risk factors for ACEi/ARB-induced ...

Telling patients how many extra days they’ll be free from an event can help with shared decision-making, experts say.

Rates of arrhythmic events and death remained common in patients indicated for implantable cardioverter defibrillator or ...

STOCKHOLM, SE / ACCESS Newswire / May 6, 2025 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRA ...

STOCKHOLM, SE / ACCESS Newswire / May 6, 2025 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists ...

Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a ...

Special Report: Dimerix has received the upfront payment of US$30 million (~A$48m) from Amicus Therapeutics after signing an ...

Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a ...

About 6.7 million adults in the U.S. are living with heart failure, and that number is expected to increase to more than 8 million by 2030.

About 6.7 million adults in the U.S. are living with heart failure, and that number is expected to increase to more than 8 ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomeruloscler ...

FILSPARI is the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA), a non-immunosuppressive therapy for the treatment of IgAN approved in Europe and is currently available in Germany, ...